{"id":740439,"date":"2023-03-15T16:19:45","date_gmt":"2023-03-15T20:19:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-reports-2022-financial-results-and-provides-a-business-update\/"},"modified":"2023-03-15T16:19:45","modified_gmt":"2023-03-15T20:19:45","slug":"matinas-biopharma-reports-2022-financial-results-and-provides-a-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-reports-2022-financial-results-and-provides-a-business-update\/","title":{"rendered":"Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update"},"content":{"rendered":"
\n

\n Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids<\/em>
\n \n <\/p>\n

\n FDA feedback from MAT2203 Type B meeting expected to impact partnership discussions and facilitate potential non-dilutive BARDA and\/or NIH funding<\/em>\n <\/p>\n

\n Conference call and webcast begin at 4:30 p.m. Eastern time today<\/em>\n <\/p>\n

BEDMINSTER, N.J., March 15, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma<\/a> (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2022 financial results and provides a business update.<\/p>\n

\u201cWe are developing our LNC delivery platform with the goal of providing safe, extrahepatic delivery of nucleic acids and small molecules,\u201d said Jerome D. Jabbour, Chief Executive Officer of Matinas. \u201cPhase 2 MAT2203 clinical trial results demonstrated the ability of our platform to efficaciously deliver a safe, well-tolerated oral form of amphotericin B with dramatic survival results. Success to-date with MAT2203 bolsters our confidence in moving forward into the delivery of nucleic acids, and we are encouraged by our progress in this area.<\/p>\n

\u201cAmong upcoming milestones, we expect data readouts from our internal programs with smaller oligonucleotides, as well as data relating to the delivery of larger oligonucleotides like mRNA through collaborations with BioNTech and National Resilience, two of the world’s leading mRNA companies,\u201d he added. \u201cImportantly, these programs will provide critical information in maximizing the potential applications for our technology, thereby advancing our strategy of developing robust internal and external product pipelines.<\/p>\n

\u201cWe are also preparing to meet with the U.S. Food and Drug Administration (FDA) to seek guidance on a Phase 3 study with MAT2203 for the treatment of invasive fungal infections (IFIs). Feedback from this meeting will be instrumental in guiding our efforts to secure non-dilutive funding from the Biomedical Advanced Research and Development Authority (BARDA) and\/or the National Institutes of Health (NIH), as well as in advancing ongoing discussions with potential partners for further development of this promising oral therapy for treating life-threatening fungal infections,\u201d Mr. Jabbour concluded.<\/p>\n

\n Anticipated Second Quarter 2023 Milestones<\/strong>\n <\/p>\n

\n BioNTech Collaboration <\/em>\n <\/p>\n